Literature DB >> 8255922

Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).

S M Armstrong1, O M McNulty, B Guardiola-Lemaitre, J R Redman.   

Abstract

In human delayed sleep-phase syndrome (DSPS), sleep onset and wake times occur far later than normal. In the population, DSPS may be an important contributor to complaints of sleep onset insomnia. We previously reported an animal model of DSPS in laboratory rats in which the onset of nocturnal activity is delayed by several hours [negative phase angle difference (PAD)]. The effect of melatonin 1 mg/kg SC and S20098 (Servier) 1 and 3 mg/kg on the negative PAD was investigated over 22 days of injections. In comparison to control injections of dimethylsulfoxide (DMSO), both melatonin and S20098 over approximately 9 days phase advanced the onset of activity toward the onset of darkness. At cessation of injections, activity onset delayed over approximately 11 days back toward, but as a group did not reach the original PAD. This effect of melatonin on the phase angle of entrained rats is consistent with its effects on delayed sleep in humans. It is likely, therefore, that S20098 may be of use to ameliorate DSPS in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8255922     DOI: 10.1016/0091-3057(93)90315-k

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  19 in total

Review 1.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

Review 2.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

3.  Circadian periods of sensitivity for ramelteon on the onset of running-wheel activity and the peak of suprachiasmatic nucleus neuronal firing rhythms in C3H/HeN mice.

Authors:  Oliver Rawashdeh; Randall L Hudson; Iwona Stepien; Margarita L Dubocovich
Journal:  Chronobiol Int       Date:  2011-02       Impact factor: 2.877

Review 4.  Melatonin and its receptors: a new class of sleep-promoting agents.

Authors:  Karl Doghramji
Journal:  J Clin Sleep Med       Date:  2007-08-15       Impact factor: 4.062

5.  Agomelatine: The evidence for its place in the treatment of depression.

Authors:  Daniela Eser; Thomas C Baghai; Hans-Jürgen Möller
Journal:  Core Evid       Date:  2010-06-15

Review 6.  Bipolar disorder: candidate drug targets.

Authors:  Carlos A Zarate; Husseini K Manji
Journal:  Mt Sinai J Med       Date:  2008 May-Jun

7.  Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT1 receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light.

Authors:  Jana Tchekalarova; Lidia Kortenska; Natasha Ivanova; Milena Atanasova; Pencho Marinov
Journal:  Psychopharmacology (Berl)       Date:  2019-11-13       Impact factor: 4.530

8.  Agomelatine: protecting the CNS from the effects of stress.

Authors:  Stefania Maccari; Ferdinando Nicoletti
Journal:  CNS Neurosci Ther       Date:  2011-10       Impact factor: 5.243

9.  Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors.

Authors:  Michel Bourin; Elisabeth Mocaër; Roger Porsolt
Journal:  J Psychiatry Neurosci       Date:  2004-03       Impact factor: 6.186

10.  Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.

Authors:  Amandine Descamps; Colette Rousset; Mark J Millan; Mark Millan; Michael Spedding; Philippe Delagrange; Raymond Cespuglio
Journal:  Psychopharmacology (Berl)       Date:  2009-04-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.